Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass index (BMI) of 18 to 38 kilogram/square meter (kg/m\^2) and weight \>= 40 kg at screening~* Documented physician-diagnosed asthma~* On high dose inhaled corticosteroid (ICS) therapy plus at least one additional allowed controller medication~* Forced expiratory volume in 1 second (FEV1) of 40% to 80% of predicted~* Evidence of uncontrolled asthma~* Use of contraceptive measures~Exclusion Criteria:~* Diagnosis of mimics of asthma~* Diagnosis of occupational asthma, aspirin-sensitive asthma, asthma chronic obstructive pulmonary disease overlap syndrome, or bronchiolitis, as determined by the investigator~* Pregnant or lactating, or intending to become pregnant during the study or within 20 weeks after the last dose of MSTT1041A~* Recent history of smoking~* History or evidence of substance abuse that would pose a risk to participants safety, interfere with the conduct of the study, have an impact on the study results~* Asthma exacerbation within 4 weeks prior to screening~* Intubation for respiratory failure due to asthma within 12 months prior to screening~* Comorbid conditions that may interfere with evaluation of investigational medicinal product~* Known sensitivity to any of the active substances or their excipients to be administered during dosing~* Positive pregnancy test

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- MSTT1041A 210 mg (Type: EXPERIMENTAL): Participants will receive MSTT1041A 210 milligrams (mg), subcutaneously every 4 weeks from randomization through Week 50.
- MSTT1041A 490 mg (Type: EXPERIMENTAL): Participants will receive MSTT1041A 490 mg, subcutaneously every 4 weeks from randomization through Week 50.
- MSTT1041A 70 mg (Type: EXPERIMENTAL): Participants will receive MSTT1041A 70 mg, subcutaneously every 4 weeks from randomization through Week 50.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo matched with MSTT1041A, subcutaneously every 4 weeks from randomization through Week 50.

Based on this trial design, predict the completion outcome and termination type (if applicable).